Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Science Translational Medicine
David L PorterCarl H June

Abstract

Patients with multiply relapsed or refractory chronic lymphocytic leukemia (CLL) have a poor prognosis. Chimeric antigen receptor (CAR)-modified T cells targeting CD19 have the potential to improve on the low complete response rates with conventional therapies by inducing sustained remissions in patients with refractory B cell malignancies. We previously reported preliminary results on three patients with refractory CLL. We report the mature results from our initial trial using CAR-modified T cells to treat 14 patients with relapsed and refractory CLL. Autologous T cells transduced with a CD19-directed CAR (CTL019) lentiviral vector were infused into patients with relapsed/refractory CLL at doses of 0.14 × 10(8) to 11 × 10(8) CTL019 cells (median, 1.6 × 10(8) cells). Patients were monitored for toxicity, response, expansion, and persistence of circulating CTL019 T cells. The overall response rate in these heavily pretreated CLL patients was 8 of 14 (57%), with 4 complete remissions (CR) and 4 partial remissions (PR). The in vivo expansion of the CAR T cells correlated with clinical responses, and the CAR T cells persisted and remained functional beyond 4 years in the first two patients achieving CR. No patient in CR has relapse...Continue Reading

References

Nov 5, 1997·Nature Biotechnology·R ZuffereyD Trono
May 2, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cor H J LamersEgbert Oosterwijk
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael H KershawPatrick Hwu
Nov 9, 2006·Proceedings of the National Academy of Sciences of the United States of America·Bruce L LevineCarl H June
Feb 15, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Julie R ParkMichael C Jensen
Feb 13, 2009·Proceedings of the National Academy of Sciences of the United States of America·Carmine CarpenitoCarl H June
Apr 23, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Michael C MiloneCarl H June
Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Mar 27, 2013·The New England Journal of Medicine·Stephan A GruppCarl H June
Apr 9, 2013·Hematology/oncology Clinics of North America·John C Riches, John G Gribben
Feb 21, 2014·Science Translational Medicine·Marco L DavilaRenier Brentjens
Aug 27, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James N KochenderferSteven A Rosenberg
Oct 11, 2014·Blood·Peter DregerUNKNOWN European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp

❮ Previous
Next ❯

Citations

Apr 5, 2016·Seminars in Oncology·Joseph A FraiettaMarcela V Maus
Dec 23, 2015·American Journal of Hematology·Kanti R Rai, Preetesh Jain
Feb 18, 2016·Journal for Immunotherapy of Cancer·Michael Kalos
Nov 18, 2015·American Journal of Hematology·Noelle V Frey, David L Porter
Jan 7, 2016·Nature Medicine·Christopher A KlebanoffNicholas P Restifo
Jan 19, 2016·Blood Reviews·Nitin Jain, Susan O'Brien
Mar 11, 2016·Current Opinion in Immunology·Eugene A ZhukovskyMarcela V Maus
Mar 10, 2016·British Journal of Haematology·Antonia RotoloAnastasios Karadimitris
Feb 6, 2016·Expert Opinion on Biological Therapy·Archana Thakur, Lawrence G Lum
Sep 15, 2016·Molecular Therapy Oncolytics·Ruslan Novosiadly, Michael Kalos
Mar 16, 2016·Nature Reviews. Clinical Oncology·Danny N KhalilJedd D Wolchok
Mar 24, 2016·Nature Reviews. Clinical Oncology·Hollie J JacksonRenier J Brentjens
Mar 30, 2016·International Immunology·Matthew J Frigault, Marcela V Maus
Apr 26, 2016·The Journal of Clinical Investigation·Cameron J TurtleDavid G Maloney
May 18, 2016·Journal for Immunotherapy of Cancer·Sasha E StantonMary L Disis
May 28, 2016·Molecular Therapy Oncolytics·Daniel Abate-Daga, Marco L Davila
Jun 15, 2016·Journal of Immunology Research·Hilde AlmåsbakMohan C Vemuri
May 4, 2016·Expert Review of Hematology·Manjusha Namuduri, Renier J Brentjens
Jun 6, 2016·International Journal of Hematology·Marco L Davila, Michel Sadelain
Jun 9, 2016·The Journal of Clinical Investigation·Carlos A RamosGianpietro Dotti
May 26, 2016·Expert Opinion on Biological Therapy·Myrna R Nahas, David Avigan
May 22, 2016·Blood·Jennifer N Brudno, James N Kochenderfer
Jul 4, 2016·Current Opinion in Immunology·Michel Sadelain
Jun 21, 2016·Expert Review of Hematology·Cameron J Turtle, David G Maloney
Jul 21, 2016·Journal for Immunotherapy of Cancer·Leisha A EmensHoward L Kaufman
Aug 1, 2016·Current Hematologic Malignancy Reports·Marco Ruella, Carl H June
Aug 3, 2016·The Journal of Clinical Investigation·Partow KebriaeiLaurence J N Cooper
May 14, 2016·Clinical Pharmacology and Therapeutics·C J TurtleD G Maloney
Jul 13, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·M Kazim PanjwaniNicola J Mason
May 11, 2016·Journal of Cellular Physiology·Albert T GacerezCharles L Sentman
Aug 20, 2016·Expert Review of Hematology·Saveria CapriaAlessandro Pulsoni
Sep 2, 2016·Journal of Translational Medicine·Raffaele FrazziAlfredo Cesario

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

CAR-T cells

Chimeric antigen receptor (CAR) T cells are cells that are genetically engineered to recognize and target specific proteins. The ability of these cells to recognize cancer antigens and eliminate tumor cells have transformed cancer immunotherapy approaches. Here is the latest research on CAR-T cells.

Related Papers

The New England Journal of Medicine
Shannon L MaudeStephan A Grupp
Best Practice & Research. Clinical Haematology
Stephan A Grupp
Hematology/oncology Clinics of North America
Marco L Davila, Renier J Brentjens
© 2021 Meta ULC. All rights reserved